Lenvima Plus Keytruda 'Stood the Test of Time' for Kidney Ca

Longer follow-up data showed that Lenvima plus Keytruda still outperformed Sutent in the treatment of patients with advanced renal cell carcinoma.

Related Keywords

Texas , United States , Thomas Hutson , Lenvima Keytruda , Baylor Charlesa Sammons Cancer Center , , Texas Oncology Baylor Charles , Cancer Center , Lenvima Keytruda Continues , Show Benefit , Advanced Kidney , Asco Annual Meeting , Kidney Cancer ,